MINDCURE to Present at the Benzinga Healthcare Small Cap Conference

Rhea-AI Summary

Mind Cure Health Inc. (CSE: MCUR, OTCQB: MCURF) announced that its President & CEO, Kelsey Ramsden, will present at the Benzinga Healthcare Small Cap Conference on September 29, 2021, at 4:00 pm ET. Investors can register for the virtual event here. Ramsden will also hold one-on-one meetings with investors during the conference. Additionally, the company granted 10,000 stock options at $0.34 per share and issued 59,296 common shares to a consultant at $0.38 each.

VANCOUVER, BC, Sept. 28, 2021 /PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research in psychedelics, today announced that Kelsey Ramsden, President & CEO of MINDCURE, will present at the Benzinga Healthcare Small Cap Conference, which is being held virtually on September 29-30, 2021. Investors can register for the conference here.

In addition, Ms. Ramsden will participate in one-on-one investor meetings during the conference. To schedule a one-on-one meeting, please contact KCSA Strategic Communications at MindCure@kcsa.com.  

Benzinga Healthcare Small Cap Conference Presentation
Date: Wednesday, September 29, 2021
Time: 4:00 pm ET
Speaker: Kelsey Ramsden, President & CEO of MINDCURE
Link: Healthcare: September 29-30 - Benzinga Small Cap Conference 

In other news, the Company also announces it has granted a total of 10,000 stock options to certain employees pursuant to the terms the Company's long term incentive plan ("Plan"). The stock options are exercisable at a price of $0.34 per share, and are subject to the terms of the Plan. The Company further announces it has issued 59,296 common shares to a consultant at an agreed-upon price of $0.38 per share.

About Mind Cure Health Inc.
MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The Company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based psychedelic-assisted therapies globally. Learn more at mindcure.com, and follow us on LinkedIn, Facebook, Twitter, and Instagram.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information

Certain information presented in this news release may constitute "forward-looking information" within the meaning of applicable securities laws regarding MINDCURE and its business. Forward-looking information generally can be identified by the use of terms and phrases such as "anticipate", "believe", "could", "estimate", "expect", "feel", "intend", "may", "plan", "predict", "project", "subject to", "will", "would", and similar terms and phrases.

Forward-looking information is based on a number of key expectations and assumptions made by management of MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE's business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE's business; there will be a demand for MINDCURE's products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; and that MINDCURE will advance wellness worldwide.

Forward-looking information is provided for the purpose of presenting information about management's current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information inherently entails known and unknown risks and uncertainties about the future and actual results, and involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Although MINDCURE has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those described in forward-looking information presented, there may be other factors that cause results, performance or achievements to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements as no forward-looking information can be guaranteed. 

Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and MINDCURE does not undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.

View original content to download multimedia:https://www.prnewswire.com/news-releases/mindcure-to-present-at-the-benzinga-healthcare-small-cap-conference-301386275.html

SOURCE Mind Cure Health Inc.

FAQ

When will Mind Cure Health present at the Benzinga Healthcare Small Cap Conference?

Mind Cure Health will present on September 29, 2021, at 4:00 pm ET.

Who is the speaker for Mind Cure Health at the conference?

Kelsey Ramsden, President & CEO of Mind Cure Health, will be the speaker.

How can investors register for the Benzinga Healthcare Small Cap Conference?

Investors can register for the conference here.

What stock options did Mind Cure Health recently grant?

Mind Cure Health granted a total of 10,000 stock options at an exercise price of $0.34 per share.

What recent share issuance did Mind Cure Health report?

The company issued 59,296 common shares to a consultant at a price of $0.38 per share.